Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 3/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26408 | 1.00 | LOXL2 (0.53) | LOXL2IDO1TSHRALDH1A1CYP2C19 | |
| SCHEMBL2268068 | 1.00 | LOXL2 (0.53) | LOXL2IDO1TSHRALDH1A1CYP2C19 | |
| SCHEMBL10522155 | 0.80 | TSHR (0.54) | TSHRALDH1A1CYP2C19POLBLMNA | |
| SCHEMBL10522164 | 0.80 | TSHR (0.54) | TSHRALDH1A1CYP2C19POLBLMNA | |
| SCHEMBL17045236 | 0.78 | LOXL2 (0.57) | LOXL2IDO1TSHRALDH1A1CYP2C19 | |
| SCHEMBL8986807 | 0.78 | LOXL2 (0.62) | LOXL2IDO1KCNJ1KCNH2 | |
| SCHEMBL11601065 | 0.78 | LOXL2 (0.62) | LOXL2IDO1KCNJ1KCNH2 | |
| SCHEMBL11369488 | 0.78 | LOXL2 (0.57) | LOXL2IDO1TSHRALDH1A1CYP2C19 | |
| SCHEMBL3844658 | 0.78 | LOXL2 (0.57) | LOXL2IDO1TSHRALDH1A1CYP2C19 | |
| SCHEMBL17045214 | 0.78 | LOXL2 (0.57) | LOXL2IDO1TSHRALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | VOYAGER PHARMACEUTICAL CORPORATION (US) | 2011-08-11 | — | — | US | claimed |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | VOYAGER PHARMACEUTICAL CORPORATION | 2008-07-17 | — | — | US | claimed |
| EP-1078002-B1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LAB (US) | 2008-05-21 | — | — | EP | claimed |
| US-20050124548-A1 | Peptide antiangiogenic drugs | HENKIN JACK (US) | 2005-06-09 | — | — | US | claimed |
| US-6777535-B1 | USEFUL FOR TREATING CONDITIONS WHICH ARISE OR ARE EXACERBATED BY ANGIOGENESIS | ABBOTT LABORATORIES | 2004-08-17 | — | — | US | claimed |
| US-6753408-B1 | DRUGS USED FOR THERAPY | ABBVIE INC. | 2004-06-22 | — | — | US | claimed |
| US-6716963-B1 | OLIGOPEPTIDES | ABBOTT LABORATORIES | 2004-04-06 | — | — | US | claimed |
| EP-1242455-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2002-09-25 | — | — | EP | claimed |
| EP-1232183-A2 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2002-08-21 | — | — | EP | claimed |
| US-6388081-B1 | 4-substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries | LION BIOSCIENCE AG (DE) | 2002-05-14 | — | — | US | claimed |
| EP-0182262-A2 | Nona and decapeptide analogs of LHRH useful as LHRH antagonists | SYNTEX (U.S.A.) INC. (US) | 1986-05-28 | — | — | EP | claimed |
| EP-0002236-B1 | PEPTIDES, THEIR SALTS, THEIR ACID ADDITION SALTS, PHARMACEUTICAL FORMULATIONS CONTAINING THEM AND THEIR USE AS MORPHINE ANTAGONISTS AND ANAESTHETICS | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-02-05 | — | — | EP | claimed |
| US-4481190-A | LUTEINIZING HORMONE RELEASING HORMONE | SYNTEX (U.S.A.) INC. (US) | 1984-11-06 | — | — | US | claimed |
| EP-0111841-A1 | LHRH preparations for intranasal administration | SYNTEX (U.S.A.) INC. (US) | 1984-06-27 | — | — | EP | claimed |
| EP-0097031-A2 | Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists, their preparation and compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1983-12-28 | — | — | EP | claimed |
| EP-0000559-B1 | PENTAPEPTIDE-N-ALKYLAMIDES AND THEIR ACID ADDITION SALTS, METHODS FOR PREPARATION OF THESE COMPOUNDS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | THE WELLCOME FOUNDATION LIMITED (GB) | 1983-10-05 | — | — | EP | claimed |
| US-4314936-A | BY MEASUREM,ENT OF FLUORESENCE | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 1982-02-09 | — | — | US | claimed |
| EP-0002236-A1 | Peptides, their salts, their acid addition salts, pharmaceutical formulations containing them and their use as morphine antagonists and anaesthetics | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-06-13 | — | — | EP | claimed |
| EP-0000559-A1 | Pentapeptide-N-alkylamides and their acid addition salts, methods for preparation of these compounds and pharmaceutical formulations containing them | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-02-07 | — | — | EP | claimed |
| US-4108987-A | DIGESTIVE AIDS FOR HERBIVOROUS ANIMALS | MERCK & CO., INC. (US) | 1978-08-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | GNRHR, GRIN1, GRIN3A | LOXL2 4664/4885IDO1 896/4885TSHR 342/4885 |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | GNRHR, GRIN1, GRIN3A | LOXL2 4664/4885IDO1 896/4885TSHR 342/4885 |
| US-20050124548-A1 | Peptide antiangiogenic drugs | VEGFA, NPPA, FLT1 | LOXL2 4547/4885IDO1 4057/4885TSHR 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.